HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
HERON THERAPEUTICS, INC. /DE/
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.36−0.00 (-0.03%)
Close on Oct 19, 2026
- Market cap
- $68.69M
- P/E (TTM)
- –
- Dividend yield
- –
HERON THERAPEUTICS, INC. /DE/ revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CINVANTI | $21.79M | $20.54M | $22.92M | $23.96M | $24.14M | $25.74M | $26.87M | $22.66M | $24.93M | $25.62M | $24.27M | $23.27M | 57.9% | -9.7% |
| ZYNRELEF | $11.06M | $10.24M | $12.53M | $9.31M | $8.19M | $8.04M | $8.46M | $6.25M | $5.83M | $5.01M | $5.69M | $4.37M | 29.4% | +35.0% |
| APONVIE | $4.28M | $3.39M | $3.81M | $3.03M | $2.46M | $2.26M | $1.93M | $1.14M | $1.02M | $425.00K | $470.00K | $353.00K | 11.4% | +73.6% |
| SUSTOL | $540.00K | $547.00K | $1.33M | $1.91M | $2.40M | $2.86M | $3.52M | $2.76M | $4.25M | $3.62M | $3.80M | $3.44M | 1.4% | -77.5% |
By region
From the segment and revenue-disaggregation notes of Heron Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.